Time filter

Source Type

Castro I.,Complexo Hospitalario Universitario Of Ourense | Estevez P.,Complexo Hospitalario Universitario Of Vigo | Estevez P.,Ibiv Institute Of Biomedical Research Of Vigo | Cubiella J.,Complexo Hospitalario Universitario Of Ourense | And 21 more authors.
Digestive Diseases and Sciences | Year: 2015

Background: Colorectal cancer screening effect on right-sided colorectal neoplasia is limited. We compared fecal immunochemical test and simulated sigmoidoscopy diagnostic accuracy for advanced right-sided neoplasia detection.Methods: We analyzed 1,292 individuals with complete screening colonoscopy with a fecal immunochemical test determination before colonoscopy. Sigmoidoscopy and “hybrid strategy” (sigmoidoscopy or fecal hemoglobin concentration ≥20 µg hemoglobin/g) diagnostic yield were simulated according to UK Flexible Sigmoidoscopy, Screening for COlon REctum (SCORE), and Norwegian Colorectal Cancer Prevention (NORCCAP) trials criteria to complete colonic examination. We compared sensitivity and specificity of both strategies and of “hybrid strategy” for advanced right-sided neoplasia with McNemar test.Results: An advanced right-sided neoplasia was detected in 47 (3.6 %) subjects. A fecal hemoglobin concentration ≥20 µg hemoglobin/g was determined in 6.6 % of the subjects and 10.1, 12.7, and 23.5 % met UK, SCORE, and NORCCAP criteria, respectively. Fecal immunochemical test was statistically more specific than sigmoidoscopy strategies (93.8 %, UK 90.3 %, SCORE 87.7 %, NORCCAP 77.8 %; p < 0.001). In contrast, fecal immunochemical test sensitivity for advanced right-sided neoplasia (17 %) was not statistically different than UK (21.3 %; p = 0.7) or SCORE (23.4 %; p = 0.5), although it was inferior than NORCCAP strategy (42.5 %; p < 0.001). Adding fecal immunochemical test to sigmoidoscopy increased number of positives (8.5–25.7 %), sensitivity (10–30 %), and significantly reduced advanced right-sided neoplasia specificity (p < 0.001).Conclusions: Fecal immunochemical test and sigmoidoscopy diagnostic yield for advanced right-sided neoplasia are low. Fecal immunochemical test is more specific than sigmoidoscopy but less sensitive than sigmoidoscopy according to NORCCAP criteria. © 2014, Springer Science+Business Media New York.

Fernandez A.,Hospital POVISA | Hernandez V.,Complexo Hospitalario Universitario Of Vigo | Hernandez V.,IBIV Institute of Biomedical Research of Vigo | Martinez-Ares D.,Complexo Hospitalario Universitario Of Vigo | And 20 more authors.
Gastroenterologia y Hepatologia | Year: 2015

Introduction: Incidence of inflammatory bowel disease (IBD) is increasing progressively. Few recent epidemiological prospective studies are available in Spain. The Epicom study, a population-based inception cohort of unselected IBD patients developed within the European Crohn's and Colitis Organization, was started in 2010. Vigo is the only Spanish area participating. Objective: To describe the incidence of IBD in the Vigo area and the phenotypical characteristics at diagnosis and to compare them with previous data available in Spain. Material and methods: Epidemiological, descriptive, prospective, and population-based study. All incident cases of IBD during 2010 and living in the Vigo area at diagnosis were included. The Copenhagen Diagnostic criteria were used to define cases. Background population at the start of the study was 579,632 inhabitants. Data were prospectively entered in the EpiCom database. Results: A total of 106 patients were included (57.5% men, median age 39.5 years). Of them 53 were diagnosed of as Crohn's disease (CD), 47 ulcerative colitis (UC) and six IBD unclassified (IBDU). The incidence rate per 100,000 per year for patients aged 15 years or older was 21.4 (10.8 for CD, 9.4 for UC, 1.2 IBDU). Including pediatric population incidence rates were 18.3 (10.3 CD, 8.7 UC, 1.2 IBDU). Median time since onset of symptoms until diagnosis was 2 months. Conclusions: The incidence rate of IBD in Vigo is the highest compared to former Spanish cohorts, especially in CD patients. Median time since onset of symptoms until diagnosis is relatively short. Introducción: Objetivo: Material y métodos: Resultados: Conclusiones: © 2015 Elsevier España, S.L.U. and AEEH y AEG.

Cubiella J.,Complexo Hospitalario Universitario Of Ourense | Castro I.,Complexo Hospitalario Universitario Of Ourense | Hernandez V.,Complexo Hospitalario Universitario Of Vigo | Hernandez V.,IBIV Institute of Biomedical Research of Vigo | And 23 more authors.
Cancer Epidemiology Biomarkers and Prevention | Year: 2014

Background: Fecal immunochemical test (FIT) diagnostic accuracy for colorectal adenoma detection in colorectal cancer screening is limited.Methods: We analyzed 474 asymptomatic subjects with adenomas detected on colonoscopy in two blinded diagnostic tests studies designed to assess FIT diagnostic accuracy. We determined the characteristics of adenomas (number, size, histology, morphology, and location) and the risk of metachronous lesions (according to European guidelines). Finally, we performed a logistic regression to identify those variables independently associated with a positive result.Results: Advanced adenomas were found in 145 patients (75.6% distal and 24.3% only proximal to splenic flexure). Patients were classified as low (59.5%), intermediate (30.2%), and high risk (10.3%) according to European guidelines. At a 100-ng/mLthreshold, FIT was positive in 61 patients (12.8%). Patients with advanced adenomas [odds ratio (OR), 8.8; 95% confidence interval (CI), 4.76-16.25], distal advanced adenomas (OR, 6.7; 95% CI, 1.9-8.8), high risk (OR, 20.1; 95% CI, 8.8-45.8), or intermediate risk lesions (OR, 6; 95% CI, 2.9-12.4) had more probabilities tohave apositive test.The characteristics ofadenomas independently associatedwerenumber of adenomas (OR, 1.22; 95% CI, 1.04-1.42), distal flat adenomas (OR, 0.44; 95% CI, 0.21-0.96), pedunculated adenomas (OR, 2.28; 95%CI, 1.48-3.5), and maximumsize of distal adenomas (mm; OR, 1.24; 95%CI, 1.16-1.32).Conclusions: European guidelines classification and adenoma location correlates with the likelihood of a positive FIT result.Impact: This information allows us to understand the FIT impact in colorectal cancer prevention. Likewise, it should be taken into account in the development of new colorectal adenomas biomarkers. © 2014 AACR.

Loading Ibiv Institute Of Biomedical Research Of Vigo collaborators
Loading Ibiv Institute Of Biomedical Research Of Vigo collaborators